CELESTINA HERNANDEZ: Open Payments
NPI 1780450825 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,591 in 165 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $2,596 · 2025 $3,591
Food & beverage: $3,591
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 28 | $715 |
| Madrigal Pharmaceuticals | 17 | $658 |
| ABBVIE INC. | 38 | $583 |
| Janssen Scientific Affairs, LLC | 2 | $285 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $220 |
| Ipsen Biopharmaceuticals, Inc | 10 | $156 |
| Celltrion USA Inc. | 7 | $155 |
| Lilly USA, LLC | 7 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $145 |
| Ardelyx, Inc. | 5 | $109 |
Products named: TREMFYA, REZDIFFRA, LINZESS, XIFAXAN, IQIRVO, VEGZELMA, OMVOH, CREON.
Industry payments across TX — which companies pay providers there.
